Progress in systemic therapy of advanced hepatocellular carcinoma
Open Access
- 1 January 2016
- journal article
- research article
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 22 (29), 6582-6594
- https://doi.org/10.3748/wjg.v22.i29.6582
Abstract
Primary liver cancer, mainly consisting of hepatocellular carcinoma (HCC), is one of common malignancies worldwide, and prevalent among the Chinese population. A diagnosis of early stage HCC has proven to be very difficult because of its insidious feature in onset and development. At the time of diagnosis, most HCC cases are locally advanced and/or distant metastatic, which results in difficulty to be treated and poor prognosis. For advanced HCC, systemic therapy is frequently adopted as an important palliative method. In recent years, clinical studies and observations have often reported about systemic anti-cancer therapy of advanced HCC, including molecular target therapy, systemic chemotherapy and immunotherapy. In this article, we review these treatment modalities to provide a reference for clinicians.Keywords
This publication has 68 references indexed in Scilit:
- Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancerNature Medicine, 2013
- A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid TumorsClinical Cancer Research, 2012
- The Oncolytic Poxvirus JX-594 Selectively Replicates in and Destroys Cancer Cells Driven by Genetic Pathways Commonly Activated in CancersMolecular Therapy, 2012
- Phase I Dose-Finding Study of Pazopanib in Hepatocellular Carcinoma: Evaluation of Early Efficacy, Pharmacokinetics, and PharmacodynamicsClinical Cancer Research, 2011
- c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinomaHepatology, 2011
- 665 A PHASE I/II STUDY OF FORETINIB, AN ORAL MULTIKINASE INHIBITOR TARGETING MET, RON, AXL, TIE-2 AND VEGFR IN ADVANCED HEPATOCELLULAR CARCINOMA (HCC)Journal of Hepatology, 2011
- Neoadjuvant sorafenib combined with gemcitabine plus oxaliplatin in advanced hepatocellular carcinomaWorld Journal of Gastroenterology, 2011
- A randomised phase II study of pegylated arginine deiminase (ADI-PEG 20) in Asian advanced hepatocellular carcinoma patientsBritish Journal of Cancer, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008